טוען...
Targeting dendritic cells in situ for breast cancer immunotherapy
We have recently developed a protein vaccine against breast cancer in which HER2 is delivered to dendritic cells (DCs) in vivo through receptors expressed on their surface. Our results indicate that this is a promising approach to induce durable, broad and integrated immunity against breast cancer.
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Landes Bioscience
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3518515/ https://ncbi.nlm.nih.gov/pubmed/23243606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.20982 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|